RecruitingMacular Edema Secondary to Inflammation
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Eligible age
18+ yrs
Accepts
All genders
Locations
24 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Sponsor: Kodiak Sciences Inc
You may qualify if…
- ✓ Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥400 microns on SD-OCT in Study Eye.
- ✓ Definitive presence of Intraretinal Fluid and/or Subretinal Fluid on SD-OCT in the Study Eye.
- ✓ BCVA ETDRS score of ≥25 and ≤70 letters (between 20/40 and 20/320 Snellen equivalent) in the Study Eye.
- ✓ Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.
You may not qualify if…
- ✕ Macular Edema in the Study Eye secondary to diabetic retinopathy, RVO, or wAMD.
- ✕ Active or suspected ocular or periocular infection in either eye.
- ✕ Any history of or active occlusive retinal vasculitis in either eye.
Where it's recruiting
Arizona
Phoenix · Scottsdale
California
Bakersfield · Glendale · La Jolla · Los Angeles …
Colorado
Denver
Connecticut
Greenwich · Manchester · Waterford
Florida
Altamonte Springs · Fort Lauderdale · St. Petersburg
Illinois
Elmhurst
Indiana
Carmel
Maryland
Hagerstown
Massachusetts
Boston
Minnesota
Saint Louis Park
Missouri
St Louis
New Jersey
Palisades Park
Source: ClinicalTrials.gov · NCT06990399 · last updated 2026-05-18